PRGO

Perrigo Company plc - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 28, 2026. Perrigo Company plc is a leading pure-play self-care company. During this quarter, the Company implemented a new operating model, transitioning from geographic segments to product category-based segments: Self Care, Specialty Care, and Infant Formula. The Company also completed the sale of its Dermacosmetics business on April 30, 2026, shortly after the period end.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7.2% ($74.7 million) primarily due to lower consumption in the U.S. and Europe (driven by lower seasonal cough/cold incidence) and the prior-year sale of the Richard Bittner Business. This was partially offset by a $30.1 million favorable foreign currency impact.
• Significant Impairment: The Company recorded a $330.8 million goodwill impairment charge following a segment reorganization. This impacted the Women's Health ($77.4M), Infant Formula ($66.3M), and Oral Care ($187.2M) reporting units.
• Restructuring Costs: Restructuring charges increased to $75.1 million from $29.4 million, driven by the new "Operational Enhancement Program" targeting a 7% workforce reduction.
• Tariff Recovery: The Company recognized a $21 million benefit in gross profit related to the recovery of previously paid tariffs following a U.S. Supreme Court ruling.
• Segment Performance:
  • Self Care: Sales down 11.5%; Operating income down 39.3%.
  • Specialty Care: Sales up 4.0%; Operating income up 31.4%.
  • Infant Formula: Sales up 2.1%; Operating income turned negative ($(7.4)M) due to manufacturing headwinds.

Guidance, Outlook, and Risks

• Strategic Initiatives: The Company is executing a "Three-S" plan (Stabilizing, Streamlining, Strengthening). The new Operational Enhancement Program targets $80-$100 million in annual pre-tax cost savings, with cash costs of $80-$90 million.
• Divestiture: The sale of the Dermacosmetics business was completed for up to €332.6 million (€305.6M upfront + earn-outs).
• Debt Refinancing: On March 20, 2026, the Company entered an Amended and Restated Credit Agreement, extending the Revolver maturity to 2031 and eliminating credit spread adjustments. Term A loans were prepaid.
• Credit Ratings: Ratings were downgraded or outlooks adjusted to negative by S&P (B+), Fitch (BB), and Moody's (Ba3) in March 2026. This triggered an interest rate increase on the 2030 Notes to 5.150%.
• Key Risks:
  • Infant Formula: Ongoing regulatory scrutiny (FDA Form 483 issued Feb 2026) and a strategic review of the business.
  • Litigation: Significant exposure from price-fixing lawsuits related to the former Rx business ($43M accrual) and securities litigation regarding infant formula disclosures.
  • Geopolitics: Conflicts in Ukraine and the Middle East impacting supply chains and costs.

Investor Verification Checklist

• Impairment Sustainability: Verify the assumptions used in the goodwill impairment test, particularly for the Women's Health unit which has a passing margin of less than 10%.
• Infant Formula Turnaround: Assess the timeline and cost of resolving FDA observations and the outcome of the strategic review (potential divestiture vs. continued investment).
• Litigation Exposure: Monitor the status of the Humana bellwether trial (scheduled Sept 2026) and the IRS tax dispute appeal regarding omeprazole transfer pricing.
• Debt Covenants: Confirm continued compliance with the 3.0x net leverage ratio and 3.0x interest coverage ratio covenants given the recent operating loss.
• Cost Savings Realization: Track the execution of the Operational Enhancement Program to ensure the targeted $80-$100 million in annual savings is achieved.